Latest Hydroxyurea Stories
Data Demonstrate Hydroxyurea Therapy Offers Safe, Effective Disease Management CINCINNATI, Nov.
Young infants and toddlers with sickle cell anemia who received the drug hydroxyurea were no more likely to have cellular genetic damage than those who received a placebo or inactive medicine.
Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery will be presented today at the 53rd Annual Meeting of the American Society of Hematology.
A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.
More public awareness and education about sickle cell disease, an inherited disease that affects the blood system, is critically important.
As researchers continue to study the use of hydroxyurea as a treatment for sickle cell disease, there is more evidence to validate that it is safe and effective for children with the disease, said an expert pediatric hematologist from Baylor College of Medicine.
A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.
- A transitional zone between two communities containing the characteristic species of each.